This article is more than 5 years old. Information may no longer be current.
Top 5 online stories posted in the last month
Click Here to Manage Email Alerts
Endocrine Today compiled a list of the top five news reports posted from June 21 to July 21.
Healio.com/Endocrinology readers were interested in a new name proposed for PCOS; the CV benefit claim for Jardiance; insulin dose required with high-fat, high-protein meals; and much more.
‘Metabolic reproductive syndrome’ proposed as new name for PCOS
NEW ORLEANS — Polycystic ovary syndrome will be renamed to “metabolic reproductive syndrome” as a result of debates and surveys of women affected by the condition and the health professionals who support their care, according to a speaker here.
“It is time to assign a new name that actually reflects the complex features of the condition,” Helena J. Teede, MBBS, FRACP, PhD, professor and head of the Women’s Public Health Research Program at Monash University in Victoria, Australia, said during her presentation. “The new name needs to enhance the recognition of this major public health issue ... and can then lead to greater educational outreach and better public relations.” Read more.
FDA advisory committee splits on CV benefit claim for Jardiance
An FDA advisory panel on Tuesday voted 12 to 11 in favor of an expanded indication for the SGLT2 inhibitor Jardiance, supporting language in the prescribing information that the drug can reduce the incidence of cardiovascular death in patients with type 2 diabetes and a history of cardiovascular disease.
The decision follows an in-depth analysis of primary and secondary endpoints in the EMPA-REG Outcome trial, a randomized, double blind, placebo-controlled study that revealed a surprise CV benefit in patients with type 2 diabetes at high CV risk. The FDA requires that all diabetes drugs undergo testing for CV outcomes. Jardiance (empagliflozin, Boehringer Ingelheim/Lilly) was the first to demonstrate a CV benefit. Read more.
High-fat, high-protein meal requires high insulin dose
Meal composition along with carbohydrate count should be considered when calculating insulin dosages and may provide a foundation for new insulin-dosing algorithms for meals of varying macronutrient composition, according to study results.
Howard A. Wolpert, MD, director of the insulin pump and continuous glucose monitoring programs at Joslin Diabetes Center and associate professor of medicine at Harvard University, and colleagues evaluated 10 adults with type 1 diabetes (nine men; mean age, 60.4 years; BMI, 25.8 kg/m2; HbA1c, 7.1%; total insulin dose, 35.5 U/day). Researchers evaluated the insulin dose adjustments required for coverage of high-fat, high-protein meals. Read more.
Overweight, obesity increase risk for early death
In nearly all regions of the world, both overweight and obesity are associated with higher all-cause mortality in otherwise healthy, nonsmoking adults, with greater risk observed in men vs. women, according to new findings from a collaborative study.
“On average, overweight people lose about 1 year of life expectancy, and moderately obese people lose about 3 years of life expectancy,” Emanuele Di Angelantonio, MD, PhD, lecturer in the cardiovascular epidemiology unit at the University of Cambridge, United Kingdom, said in a press release. “We also found that men who were obese were at much higher risk for premature death than obese women. This is consistent with previous observations that obese men have greater insulin resistance, liver fat levels and diabetes risk than women.” Read more.
Recurrent DKA increases mortality risk in at-risk patients with diabetes
More than one in five patients with recurrent diabetic ketoacidosis will die within 3 years, with young, socially disadvantaged patients prescribed antidepressants most at risk for death, according to recent study findings.
“The most striking finding from this investigation is the substantial short-term risk of death associated with recurrent [diabetic ketoacidosis] admissions in patients with type 1 diabetes,” Fraser W. Gibb, MBChB, PhD, FRCP (Edin), consultant physician and honorary clinical senior lecturer at the Edinburgh Centre for Endocrinology and Diabetes, United Kingdom, and colleagues wrote. “In keeping with other modern cohorts, we found a low rate of inpatient mortality in patients presenting with [diabetic ketoacidosis]. ... However, the frequency of subsequent sudden death at home, particularly in young people, is unacceptably high.” Read more.